{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:26:09Z","timestamp":1770330369821,"version":"3.49.0"},"reference-count":75,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Proteinuria poses a significant challenge in focal segmental glomerulosclerosis (FSGS), particularly when resistant to standard treatments. Acthar\n                    <jats:sup>\u00ae<\/jats:sup>\n                    Gel, a Food and Drug Administration (FDA)-approved treatment, may be a potential option for proteinuria in nephrotic syndrome (NS) due to FSGS, particularly given the limited alternative therapies. This study assessed the cost-per-response of Acthar Gel versus standard of care (SoC) for the treatment of refractory proteinuria in NS due to FSGS among adults from a US healthcare payer perspective over a 1- to 3-year horizon.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A probabilistic, cohort-based state-transition model tracked adults with nephrotic-range proteinuria due to FSGS through clinically relevant health states in 6-month cycles. All patients entered in relapse and received either Acthar Gel or SoC. At each cycle, individuals could transition to response or remain uncontrolled, progress to renal failure, or continue in relapse; death was permitted from any state. Responders were allowed to either sustain response or experience relapse in subsequent cycles. Model inputs for clinical event rates, healthcare utilization and medical costs were sourced from the published literature, and drug costs were valued using wholesale acquisition cost. Cost-per-response was defined as total healthcare costs (drug and nondrug medical costs) per patient divided by the response rate.\n                    <jats:bold>Results:<\/jats:bold>\n                    Acthar Gel showed a lower cost-per-response ($469,735) versus cyclophosphamide ($2,140,400) and rituximab ($1,272,477) over 1\u00a0year. This advantage for Acthar Gel was sustained for 2 and 3\u00a0years. Acthar Gel was potentially a dominant treatment option at 2 and 3\u00a0years, with a lower overall cost of care and higher response rates than SoC.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    From a US healthcare payer perspective, Acthar Gel appears to be a cost-effective, value-based treatment option for adults with proteinuria in NS due to FSGS over 1 to 3\u00a0years. These findings may aid providers and payers in making informed treatment decisions when conventional therapies are ineffective for these patients.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0155","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:26:32Z","timestamp":1769595992000},"source":"Crossref","is-referenced-by-count":0,"title":["Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective"],"prefix":"10.57264","volume":"15","author":[{"given":"Jas","family":"Bindra","sequence":"first","affiliation":[{"name":"Falcon Research Group, North Potomac, MD 20878, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishveen","family":"Chopra","sequence":"additional","affiliation":[{"name":"Manticore Consultancy, Bethesda, MD 20814, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Hayes","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Niewoehner","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Panaccio","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J","family":"Wan","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"12","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2215\/CJN.02840313","article-title":"Treatment of idiopathic FSGS with adrenocorticotropic hormone gel","volume":"8","author":"Hogan J","year":"2013","unstructured":"Hogan J, Bomback AS, Mehta K Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin. J. Am. Soc. Nephrol. 8(12), 2072\u20132081 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov S","year":"2005","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J. Am. Soc. Nephrol. 16(4), 1061\u20131068 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"54","author":"Levey AS","year":"2009","unstructured":"Levey AS, Cattran D, Friedman A Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 54(2), 205\u2013226 (2009).","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 100(Suppl. 4), S1\u2013S276 (2021).","journal-title":"Kidney Int."},{"issue":"5","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ekir.2017.05.015","article-title":"Safety and efficacy of combination Acthar Gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy","volume":"2","author":"Tumlin J","year":"2017","unstructured":"Tumlin J, Galphin C, Santos R, Rovin B. Safety and efficacy of combination Acthar Gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy. Kidney Int. Rep. 2(5), 924\u2013932 (2017).","journal-title":"Kidney Int. Rep."},{"issue":"2","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ajkd.2023.02.003","article-title":"KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"82","author":"Beck LH","year":"2023","unstructured":"Beck LH Jr, Ayoub I, Caster D KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. Am. J. Kidney Dis. 82(2), 121\u2013175 (2023).","journal-title":"Am. J. Kidney Dis."},{"issue":"11","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1681\/ASN.2012040389","article-title":"Treatment of primary FSGS in adults","volume":"23","author":"Korbet SM","year":"2012","unstructured":"Korbet SM. Treatment of primary FSGS in adults. J. Am. Soc. Nephrol. 23(11), 1769\u20131776 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-4632.2009.04322.x","article-title":"Prevention and treatment of systemic glucocorticoid side effects","volume":"49","author":"Moghadam-Kia S","year":"2010","unstructured":"Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int. J. Dermatol. 49(3), 239\u2013248 (2010).","journal-title":"Int. J. Dermatol."},{"key":"e_1_3_8_11_2","unstructured":"Mallinckrodt Pharmaceuticals. Acthar\u00ae Gel prescribing information. (1952). (Revised October 2021). https:\/\/www.acthar.com\/pdf\/Acthar-PI.pdf"},{"issue":"1","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial","volume":"36","author":"Bomback AS","year":"2012","unstructured":"Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am. J. Nephrol. 36(1), 58\u201367 (2012).","journal-title":"Am. J. Nephrol."},{"key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/DDDT.S17521","article-title":"Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel","volume":"5","author":"Bomback AS","year":"2011","unstructured":"Bomback AS, Tumlin JA, Baranski J Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des. Devel. Ther. 5, 147\u2013153 (2011).","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_3_8_14_2","first-page":"125","article-title":"Adrenocorticotropic hormone analog use for podocytopathies","volume":"9","author":"Filippone EJ","year":"2016","unstructured":"Filippone EJ, Dopson SJ, Rivers DM Adrenocorticotropic hormone analog use for podocytopathies. Int. Med. Case Rep. J. 9, 125\u2013133 (2016).","journal-title":"Int. Med. Case Rep. J."},{"key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12882-016-0241-7","article-title":"Acthar Gel in the treatment of nephrotic syndrome: a multicenter retrospective case series","volume":"17","author":"Madan A","year":"2016","unstructured":"Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A. Acthar Gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrol. 17, 37 (2016).","journal-title":"BMC Nephrol."},{"issue":"4","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin BH","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 100(4), 753\u2013779 (2021).","journal-title":"Kidney Int."},{"issue":"2","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000521901","article-title":"Use of rituximab as an off-label medication in glomerular diseases: clinical perspective","volume":"31","author":"AlSahow A","year":"2022","unstructured":"AlSahow A, Al-Muhaiteeb A, Nawar H Use of rituximab as an off-label medication in glomerular diseases: clinical perspective. Med. Princ. Pract. 31(2), 133\u2013141 (2022).","journal-title":"Med. Princ. Pract."},{"key":"e_1_3_8_18_2","unstructured":"Genentech. Rituxan (rituximab): prescribing information. (2010). (cited 20 February 2025). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103705s5311lbl.pdf"},{"key":"e_1_3_8_19_2","unstructured":"UNC Kidney Center. Cyclophosphamide (Cytoxan\u00ae). (2025). (cited 20 February 2025). https:\/\/unckidneycenter.org\/kidneyhealthlibrary\/drug-information\/cyclophosphamide-cytoxan\/"},{"key":"e_1_3_8_20_2","unstructured":"Food and Drug Administration. Cyclophosphamide injection: prescribing information. (2020). (cited 20 February 2025). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212501s000lbl.pdf"},{"issue":"1","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/ajkd.1998.v32.pm9669427","article-title":"Long-term outcome in children and adults with classic focal segmental glomerulosclerosis","volume":"32","author":"Cattran DC","year":"1998","unstructured":"Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am. J. Kidney Dis. 32(1), 72\u201379 (1998).","journal-title":"Am. J. Kidney Dis."},{"issue":"8","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2215\/CJN.00570109","article-title":"Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis","volume":"4","author":"Fernandez-Fresnedo G","year":"2009","unstructured":"Fernandez-Fresnedo G, Segarra A, Gonzalez E Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 4(8), 1317\u20131323 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti P","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 25(4), 850\u2013863 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez G","year":"2021","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, Logt A-Evd The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 99(4), 986\u2013998 (2021).","journal-title":"Kidney Int."},{"issue":"1","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza FC","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381(1), 36\u201346 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1016\/j.jval.2024.03.1874","article-title":"SA27 Reduction in corticosteroid use among patients with focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy after Acthar\u00ae Gel in a large administrative claims database","volume":"27","author":"Hayes K","year":"2024","unstructured":"Hayes K, Hu FS, Fahim M, Panaccio M, Niewoehner J, Wan GJ. SA27 Reduction in corticosteroid use among patients with focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy after Acthar\u00ae Gel in a large administrative claims database. Value Health 27(6), S400 (2024).","journal-title":"Value Health"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1872515"},{"issue":"3","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.kint.2021.03.041","article-title":"The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis","volume":"100","author":"Lambourg E","year":"2021","unstructured":"Lambourg E, Colvin L, Guthrie G The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis. Kidney Int. 100(3), 636\u2013649 (2021).","journal-title":"Kidney Int."},{"key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/kidneydial3010002","article-title":"The prevalence and lived experience of pain in people undertaking dialysis","volume":"3","author":"Moore I","year":"2023","unstructured":"Moore I, Byrne P, Ilic N, Chen JH, Lambert K. The prevalence and lived experience of pain in people undertaking dialysis. Kidney Dialysis 3, 24\u201335 (2023).","journal-title":"Kidney Dialysis"},{"issue":"1","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ekir.2016.09.005","article-title":"Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management","volume":"2","author":"Shirazian S","year":"2017","unstructured":"Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F, Ricardo AC. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int. Rep. 2(1), 94\u2013107 (2017).","journal-title":"Kidney Int. Rep."},{"issue":"2","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ekir.2020.10.033","article-title":"A national registry study of patient and renal survival in adult nephrotic syndrome","volume":"6","author":"Kolb A","year":"2021","unstructured":"Kolb A, Gallacher PJ, Campbell J A national registry study of patient and renal survival in adult nephrotic syndrome. Kidney Int. Rep. 6(2), 449\u2013459 (2021).","journal-title":"Kidney Int. Rep."},{"issue":"5","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ki.2011.379","article-title":"Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis","volume":"81","author":"Coca SG","year":"2012","unstructured":"Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 81(5), 442\u2013448 (2012).","journal-title":"Kidney Int."},{"key":"e_1_3_8_33_2","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System. (2024). (cited 25 January 2025). https:\/\/usrds-adr.niddk.nih.gov\/2024\/end-stage-renal-disease\/6-mortality"},{"key":"e_1_3_8_34_2","first-page":"1131","article-title":"Prevalence and severity of pain in adult end-stage renal disease patients on chronic intermittent hemodialysis: a systematic review","volume":"10","author":"Brkovic T","year":"2016","unstructured":"Brkovic T, Burilovic E, Puljak L. Prevalence and severity of pain in adult end-stage renal disease patients on chronic intermittent hemodialysis: a systematic review. Patient Prefer. Adherence 10, 1131\u20131150 (2016).","journal-title":"Patient Prefer. Adherence"},{"issue":"6","key":"e_1_3_8_35_2","first-page":"479","article-title":"Diagnosis and management of nephrotic syndrome in adults","volume":"93","author":"Kodner C","year":"2016","unstructured":"Kodner C. Diagnosis and management of nephrotic syndrome in adults. Am. Fam. Physician 93(6), 479\u2013485 (2016).","journal-title":"Am. Fam. Physician"},{"issue":"3","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","article-title":"The increased risk of coronary heart disease associated with nephrotic syndrome","volume":"44","author":"Ordonez JD","year":"1993","unstructured":"Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 44(3), 638\u2013642 (1993).","journal-title":"Kidney Int."},{"issue":"2","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s10157-015-1149-4","article-title":"Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome","volume":"20","author":"Li SJ","year":"2016","unstructured":"Li SJ, Tu YM, Zhou CS, Zhang LH, Liu ZH. Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome. Clin. Exp. Nephrol. 20(2), 212\u2013217 (2016).","journal-title":"Clin. Exp. Nephrol."},{"key":"e_1_3_8_38_2","unstructured":"Merative LP. Micromedex\u00ae Red Book\u00ae. (2025). https:\/\/www.merative.com\/documents\/micromedex-red-book"},{"issue":"1","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1038\/s41598-023-32576-7","article-title":"Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS","volume":"13","author":"Osterholt T","year":"2023","unstructured":"Osterholt T, Todorova P, Kuhne L Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS. Sci. Rep. 13(1), 6980 (2023).","journal-title":"Sci. Rep."},{"issue":"8","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.clinthera.2017.06.007","article-title":"Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting","volume":"39","author":"Schmier J","year":"2017","unstructured":"Schmier J, Ogden K, Nickman N Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting. Clin. Ther. 39(8), 1600\u20131617 (2017).","journal-title":"Clin. Ther."},{"issue":"8","key":"e_1_3_8_41_2","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q","article-title":"Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy","volume":"43","author":"Chung JB","year":"2000","unstructured":"Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 43(8), 1841\u20131848 (2000).","journal-title":"Arthritis Rheum."},{"issue":"2","key":"e_1_3_8_42_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/OP.21.00466","article-title":"Financial burden of drugs prescribed for cancer-associated symptoms","volume":"18","author":"Gupta A","year":"2022","unstructured":"Gupta A, Nshuti L, Grewal US Financial burden of drugs prescribed for cancer-associated symptoms. JCO Oncol. Pract. 18(2), 140\u2013147 (2022).","journal-title":"JCO Oncol. Pract."},{"key":"e_1_3_8_43_2","unstructured":"US Bureau of Labor Statistics. CPI for all urban consumers. Medical care in U.S. city average all urban consumers seasonally adjusted. (2025). (cited 31 March 2025). https:\/\/data.bls.gov\/"},{"issue":"2","key":"e_1_3_8_44_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","article-title":"Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study","volume":"13","author":"Heatwole C","year":"2011","unstructured":"Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J. Clin. Neuromuscul. Dis. 13(2), 85\u201394 (2011).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome","volume":"11","author":"Winters JL","year":"2011","unstructured":"Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome. BMC Health Serv. Res. 11, 101 (2011).","journal-title":"BMC Health Serv. Res."},{"key":"e_1_3_8_46_2","unstructured":"US Bureau of Labor Statistics. Occupational employment and wage statistics. (2024). (cited 20 January 2025). https:\/\/www.bls.gov\/oes\/"},{"issue":"3","key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.joca.2015.10.006","article-title":"Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities","volume":"24","author":"Katz JN","year":"2016","unstructured":"Katz JN, Smith SR, Collins JE Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthritis Cartilage 24(3), 409\u2013418 (2016).","journal-title":"Osteoarthritis Cartilage"},{"key":"e_1_3_8_48_2","volume-title":"HCUP Statistical Brief #529","author":"Ding Y","year":"2020","unstructured":"Ding Y, Miller GE. Total expenses, total utilization, and sources of payment for outpatient prescription opioids in the U.S. Adult civilian noninstitutionalized population, 2017. HCUP Statistical Brief #529. Agency for Healthcare Research and Quality, MD, USA (April 2020)."},{"issue":"2","key":"e_1_3_8_49_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2125.2001.00348.x","article-title":"Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients","volume":"52","author":"Rahme E","year":"2001","unstructured":"Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br. J. Clin. Pharmacol. 52(2), 185\u2013192 (2001).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"e_1_3_8_50_2","first-page":"469","article-title":"Direct costs of opioid abuse in an insured population in the United States","volume":"11","author":"White AG","year":"2005","unstructured":"White AG, Birnbaum HG, Mareva MN Direct costs of opioid abuse in an insured population in the United States. J. Manag. Care Pharm. 11(6), 469\u2013479 (2005).","journal-title":"J. Manag. Care Pharm."},{"issue":"5","key":"e_1_3_8_51_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/abm\/kaac063","article-title":"Caring for people with depression: costs among 43 million commercially insured patients with or without comorbid illnesses","volume":"57","author":"Glassman JR","year":"2023","unstructured":"Glassman JR, Jauregui A, Milstein A, Kaplan RM. Caring for people with depression: costs among 43 million commercially insured patients with or without comorbid illnesses. Ann. Behav. Med. 57(5), 380\u2013385 (2023).","journal-title":"Ann. Behav. Med."},{"issue":"10","key":"e_1_3_8_52_2","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.ekir.2021.07.030","article-title":"A retrospective study of clinical and economic burden of focal segmental glomerulosclerosis (FSGS) in the United States","volume":"6","author":"Kalantar-Zadeh K","year":"2021","unstructured":"Kalantar-Zadeh K, Baker CL, Copley JB A retrospective study of clinical and economic burden of focal segmental glomerulosclerosis (FSGS) in the United States. Kidney Int. Rep. 6(10), 2679\u20132688 (2021).","journal-title":"Kidney Int. Rep."},{"issue":"8","key":"e_1_3_8_53_2","doi-asserted-by":"crossref","first-page":"100678","DOI":"10.1016\/j.xkme.2023.100678","article-title":"Hemodialysis versus peritoneal dialysis drug expenditures: a comparison within the private insurance market","volume":"5","author":"Bhatnagar A","year":"2023","unstructured":"Bhatnagar A, Niu J, Ho V, Winkelmayer WC, Erickson KF. Hemodialysis versus peritoneal dialysis drug expenditures: a comparison within the private insurance market. Kidney Med. 5(8), 100678 (2023).","journal-title":"Kidney Med."},{"key":"e_1_3_8_54_2","unstructured":"Bentley TS Ortner N. 2020 U.S. organ and tissue transplants: cost estimates discussion and emerging issues. (2020). (cited 3 December 2025). https:\/\/www.milliman.com\/en\/insight\/2020-us-organ-and-tissue-transplants"},{"issue":"10","key":"e_1_3_8_55_2","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD Research Programme","volume":"40","author":"Jha V","year":"2023","unstructured":"Jha V, Al-Ghamdi SMG, Li G Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD Research Programme. Adv. Ther. 40(10), 4405\u20134420 (2023).","journal-title":"Adv. Ther."},{"issue":"7","key":"e_1_3_8_56_2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1377\/hlthaff.2017.0174","article-title":"End-of-life medical spending in last twelve months of life is lower than previously reported","volume":"36","author":"French EB","year":"2017","unstructured":"French EB, McCauley J, Aragon M End-of-life medical spending in last twelve months of life is lower than previously reported. Health Aff. (Millwood). 36(7), 1211\u20131217 (2017).","journal-title":"Health Aff. (Millwood)."},{"issue":"3","key":"e_1_3_8_57_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdm525","article-title":"Cost of neutropenic complications of chemotherapy","volume":"19","author":"Weycker D","year":"2008","unstructured":"Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann. Oncol. 19(3), 454\u2013460 (2008).","journal-title":"Ann. Oncol."},{"key":"e_1_3_8_58_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.thromres.2015.11.033","article-title":"The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs","volume":"137","author":"Grosse SD","year":"2016","unstructured":"Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb. Res. 137, 3\u201310 (2016).","journal-title":"Thromb. Res."},{"key":"e_1_3_8_59_2","volume-title":"HCUP Statistical Brief #306","author":"Owens PL","year":"2024","unstructured":"Owens PL, Miller MA, Barrett ML, Hensche M. Overview of outcomes for inpatient stays involving sepsis, 2016\u20132021. HCUP Statistical Brief #306. Agency for Healthcare Research and Quality, MD, USA (April 2024)."},{"issue":"7","key":"e_1_3_8_60_2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/annonc\/mdp535","article-title":"Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab","volume":"21","author":"Foley KA","year":"2010","unstructured":"Foley KA, Wang PF, Barber BL Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann. Oncol. 21(7), 1455\u20131461 (2010).","journal-title":"Ann. Oncol."},{"issue":"1","key":"e_1_3_8_61_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.22341","article-title":"Hospitalization costs for acute myocardial infarction patients treated with percutaneous coronary intervention in the United States are substantially higher than Medicare payments","volume":"38","author":"Afana M","year":"2015","unstructured":"Afana M, Brinjikji W, Cloft H, Salka S. Hospitalization costs for acute myocardial infarction patients treated with percutaneous coronary intervention in the United States are substantially higher than Medicare payments. Clin. Cardiol. 38(1), 13\u201319 (2015).","journal-title":"Clin. Cardiol."},{"key":"e_1_3_8_62_2","volume-title":"HCUP Statistical Brief #279","author":"Fingar KR","year":"2021","unstructured":"Fingar KR, Reid LD. Diabetes-related inpatient stays, 2018. HCUP Statistical Brief #279. Agency for Healthcare Research and Quality, MD, USA (July 2021)."},{"issue":"4","key":"e_1_3_8_63_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/cpt.3493","article-title":"A systematic review of the costs of drug-associated acute kidney injury and potential cost savings with nephrotoxin stewardship prevention strategies","volume":"117","author":"Stottlemyer BA","year":"2024","unstructured":"Stottlemyer BA, Tran T, Suh K, Kane-Gill SL. A systematic review of the costs of drug-associated acute kidney injury and potential cost savings with nephrotoxin stewardship prevention strategies. Clin. Pharmacol. Ther. 117(4), 989\u20131004 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"e_1_3_8_64_2","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/13696998.2018.1474750","article-title":"Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population","volume":"21","author":"Rice JB","year":"2018","unstructured":"Rice JB, White AG, Johnson M Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. J. Med. Econ. 21(9), 846\u2013852 (2018).","journal-title":"J. Med. Econ."},{"key":"e_1_3_8_65_2","volume-title":"American Society of Nephrology, Kidney Week","author":"Nazareth T","year":"2017","unstructured":"Nazareth T, Kariburyo F, Kirkemo A Patients with focal segmental glomerulosclerosis (FSGS): a claims analysis of clinical and economic outcomes. Abstract: TH-PO168. Presented at: American Society of Nephrology, Kidney Week, LA, USA (2017)."},{"issue":"10","key":"e_1_3_8_66_2","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfu097","article-title":"Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience","volume":"29","author":"Ramachandran R","year":"2014","unstructured":"Ramachandran R, Kumar V, Rathi M Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Nephrol. Dial. Transplant. 29(10), 1918\u20131924 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"e_1_3_8_67_2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12882-016-0322-7","article-title":"The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series","volume":"17","author":"Kashgary A","year":"2016","unstructured":"Kashgary A, Sontrop JM, Li L The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol. 17(1), 104 (2016).","journal-title":"BMC Nephrol."},{"issue":"1","key":"e_1_3_8_68_2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1186\/s12913-022-08210-z","article-title":"Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions","volume":"22","author":"Klemencic Kozul T","year":"2022","unstructured":"Klemencic Kozul T, Yudina A, Donovan C, Pinto A, Osman C. Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions. BMC Health Serv. Res. 22(1), 904 (2022).","journal-title":"BMC Health Serv. Res."},{"issue":"1","key":"e_1_3_8_69_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ckj\/sfz054","article-title":"Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care","volume":"13","author":"Lefebvre C","year":"2020","unstructured":"Lefebvre C, Hindie J, Zappitelli M, Platt RW, Filion KB. Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care. Clin. Kidney J. 13(1), 63\u201371 (2020).","journal-title":"Clin. Kidney J."},{"issue":"3","key":"e_1_3_8_70_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.bja.2021.08.035","article-title":"Analgesic use and associated adverse events in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"128","author":"Lambourg E","year":"2022","unstructured":"Lambourg E, Colvin L, Guthrie G, Walker H, Bell S. Analgesic use and associated adverse events in patients with chronic kidney disease: a systematic review and meta-analysis. Br. J. Anaesth. 128(3), 546\u2013561 (2022).","journal-title":"Br. J. Anaesth."},{"key":"e_1_3_8_71_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/TCRM.S262843","article-title":"Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists","volume":"16","author":"Coluzzi F","year":"2020","unstructured":"Coluzzi F, Caputi FF, Billeci D Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists. Ther. Clin. Risk Manag. 16, 821\u2013837 (2020).","journal-title":"Ther. Clin. Risk Manag."},{"issue":"12","key":"e_1_3_8_72_2","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1111\/ajt.14714","article-title":"Prescription opioid use before and after kidney transplant: implications for posttransplant outcomes","volume":"18","author":"Lentine KL","year":"2018","unstructured":"Lentine KL, Lam NN, Naik AS Prescription opioid use before and after kidney transplant: implications for posttransplant outcomes. Am. J. Transplant. 18(12), 2987\u20132999 (2018).","journal-title":"Am. J. Transplant."},{"issue":"1","key":"e_1_3_8_73_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2036.1988.tb00772.x","article-title":"Cost of treating arthritis and NSAID-related gastrointestinal side-effects","volume":"2","author":"Bloom BS","year":"1988","unstructured":"Bloom BS. Cost of treating arthritis and NSAID-related gastrointestinal side-effects. Aliment. Pharmacol. Ther. 2(Suppl. 1), 131\u2013138 (1988).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"964","key":"e_1_3_8_74_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/pgmj.2005.038588","article-title":"Management of acute renal failure","volume":"82","author":"Fry AC","year":"2006","unstructured":"Fry AC, Farrington K. Management of acute renal failure. Postgrad. Med. J. 82(964), 106\u2013116 (2006).","journal-title":"Postgrad. Med. J."},{"issue":"5","key":"e_1_3_8_75_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ajt.2023.04.001","article-title":"Vital signs: health disparities in hemodialysis-associated staphylococcus aureus bloodstream infections - United States, 2017\u20132020","volume":"23","author":"Rha B","year":"2023","unstructured":"Rha B, See I, Dunham L Vital signs: health disparities in hemodialysis-associated staphylococcus aureus bloodstream infections - United States, 2017\u20132020. Am. J. Transplant. 23(5), 676\u2013681 (2023).","journal-title":"Am. J. Transplant."},{"issue":"3","key":"e_1_3_8_76_2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov S","year":"2004","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Toronto Glomerulonephritis Registry Group. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 66(3), 1199\u20131205 (2004).","journal-title":"Kidney Int."},{"issue":"26","key":"e_1_3_8_77_2","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter ME","year":"2010","unstructured":"Porter ME. What is value in health care? N. Engl. J. Med. 363(26), 2477\u20132481 (2010).","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:15:13Z","timestamp":1770286513000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.57264\/cer-2025-0155"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0155","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"e250155"}}